Carnivore–Ketogenic Diet for Inflammatory Bowel Disease
A 10-patient case series, not a trial. Six ulcerative colitis, four Crohn’s disease, all histologically confirmed, all either treated without medication or having successfully stopped medication while on a ketogenic or mostly-carnivore diet.
Results as reported: clinical improvement was universal, ranging 72 to 165 points on the Inflammatory Bowel Disease Questionnaire (IBDQ). Diets were “mostly meat, eggs, and animal fats.” Patients described the diets as “pleasurable, sustainable, and unequivocally enhance their quality of life.”
The proposed mechanism
The authors attribute the therapeutic potential to three overlapping features rather than one:
- Carbohydrate reduction — weight loss and glycemic control in obesity, metabolic syndrome, pre-diabetes and diabetes.
- Elimination by restriction — the diet’s narrowness removes “problem” foods that may act as immune triggers. (Note this is a confound as much as a mechanism.)
- Ketone bodies as signalling molecules, which is the interesting one — described as “akin to hormones as much as they are fuel substrates,” regulating immunity and metabolism through cell-surface receptors, inflammasome inhibition, HDAC inhibition, epigenetic regulation, and lysine β-hydroxybutyrylation on more than 1,000 different proteins.
They situate it against a Harvard cohort of 2,029 subjects on a carnivore diet for ≥6 months, which reported “few adverse effects and instead… health benefits and high satisfaction,” and against literature showing an inverse association between intestinal ketone levels and IBD activity.
How much weight it carries
⚠️ Read the methods before the conclusion. This is a case series of ten, and the crucial detail is recruitment: participants were recruited through a social media survey, with inclusion requiring that the diet had already worked. That is selection on the outcome — the design can only produce responders, and it cannot tell you the denominator of people who tried the same diet and did not improve. It establishes that responders exist and proposes a mechanism worth testing; it cannot establish efficacy, and the authors frame it as “hold promise” rather than as evidence of effect.
⚠️ Outcomes are self-reported quality-of-life scores (IBDQ), not endoscopic or histologic remission.
The honest summary: a hypothesis-generating paper with a genuinely interesting proposed mechanism, published in a legitimate open-access journal, whose design is the weakest part and whose ketone-signalling section is the strongest.
Connections
- The ketone-as-signalling-molecule material is the portable part — it generalizes well beyond IBD and is the reason the paper is worth keeping.
Where this came from
- Added directly to the collection.
10 pages. A copy is archived locally against link rot; the header links the original source.